Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsAbi Vijenthira, Lisa K. Hicks, John C. Riches et al.|Blood|2020Cited by 657
Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 5
CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 2
PHGDH is required for germinal center formation and is a therapeutic target in <i>MYC</i> -driven lymphomaAnnalisa D’Avola, John C. Riches|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 0